Literature DB >> 9926800

Resuscitation of the injured patient with polymerized stroma-free hemoglobin does not produce systemic or pulmonary hypertension.

J L Johnson1, E E Moore, P J Offner, J B Haenel, G A Hides, D Y Tamura.   

Abstract

BACKGROUND: Hemoglobin-based blood substitutes appear poised to deliver the promise of a universally compatible, disease-free alternative to banked blood. However, vasoconstriction following administration of tetrameric hemoglobins has been problematic, likely because of nitric oxide binding. Polymerized hemoglobin is effectively excluded from the abluminal space because of its size, and is thus less likely to perturb vasorelaxation. We therefore hypothesized that hemodynamic responses would be no different in injured patients receiving polymerized hemoglobin versus banked blood.
METHODS: Injured patients requiring urgent transfusion were randomized to receive either polymerized hemoglobin or banked blood. Systemic arterial pressure, pulmonary arterial pressure, cardiac index, pulmonary capillary wedge pressure, systemic vascular resistance, and pulmonary vascular resistance were measured serially.
RESULTS: There was no difference in any of the measured hemodynamic parameters between patients resuscitated with polymerized hemoglobin versus blood.
CONCLUSIONS: Polymerized hemoglobin given in large doses to injured patients lacks the vasoconstrictive effects reported in the use of other hemoglobin-based blood substitutes. This supports the continued investigation of polymerized hemoglobin in injured patients requiring urgent transfusion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9926800     DOI: 10.1016/s0002-9610(98)00275-x

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  9 in total

Review 1.  Haemoglobin-based oxygen carriers: research and reality towards an alternative to blood transfusions.

Authors:  Andrea Mozzarelli; Luca Ronda; Serena Faggiano; Stefano Bettati; Stefano Bruno
Journal:  Blood Transfus       Date:  2010-06       Impact factor: 3.443

2.  Role of nitric oxide scavenging in vascular response to cell-free hemoglobin transfusion.

Authors:  Kenji Sampei; John A Ulatowski; Yoshio Asano; Herman Kwansa; Enrico Bucci; Raymond C Koehler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-05-13       Impact factor: 4.733

3.  Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers.

Authors:  Amy G Tsai; Pedro Cabrales; Belur N Manjula; Seetharama A Acharya; Robert M Winslow; Marcos Intaglietta
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

4.  Hemoglobin-based oxygen carriers in trauma care: scientific rationale for the US multicenter prehosptial trial.

Authors:  Ernest E Moore; Aaron M Cheng; Hunter B Moore; Tomohiko Masuno; Jeffrey L Johnson
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

Review 5.  A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers.

Authors:  Jiin-Yu Chen; Michelle Scerbo; George Kramer
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

6.  Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients.

Authors:  Alan T Tinmouth; Lauralynn A McIntyre; Robert A Fowler
Journal:  CMAJ       Date:  2008-01-01       Impact factor: 8.262

7.  The USA Multicenter Prehosptial Hemoglobin-based Oxygen Carrier Resuscitation Trial: scientific rationale, study design, and results.

Authors:  Ernest E Moore; Jeffrey L Johnson; Frederick A Moore; Hunter B Moore
Journal:  Crit Care Clin       Date:  2009-04       Impact factor: 3.598

Review 8.  Surgical management in treatment of Jehovah's witness in trauma surgery in Indian subcontinent.

Authors:  Renu Kumari
Journal:  J Emerg Trauma Shock       Date:  2014-07

Review 9.  Alternatives to blood in the 21st century.

Authors:  Stephen M Cohn
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.